打开APP

Navitor获得2350万美元研究mTOR通路

  1. mTOR
  2. Navitor
  3. 融资

来源:生物谷 2014-06-20 09:28

最近位于美国麻省坎布里奇市的生物技术公司Navitor公司宣布公司在第一轮融资中获得了2350万美元的资金用于研究新的疾病通路.研究人员将对mTOR通路展开研究,这种通路与许多疾病相关,许多疾病都是由于其中一条通路mTORC1出现问题导致的。但是目前许多药物会同时阻断mTORC1通路和mTORC2通路。因此Navitor的研究人员希望能够找到精确靶向mTORC1通路的药物分子。这一工作也得到了麻省

2014年6月20日讯 /生物谷BIOON/ --最近位于美国麻省坎布里奇市的生物技术公司Navitor公司宣布公司在第一轮融资中获得了2350万美元的资金用于研究新的疾病通路.研究人员将对mTOR通路展开研究,这种通路与许多疾病相关,许多疾病都是由于其中一条通路mTORC1出现问题导致的。但是目前许多药物会同时阻断mTORC1通路和mTORC2通路。因此Navitor的研究人员希望能够找到精确靶向mTORC1通路的药物分子。这一工作也得到了麻省理工教授David Sabatini的加盟。公司希望通过自己的研究在糖尿病等领域做出突破,并借此吸引大型医药公司的参与。

Navitor公司前身是George Vlasuk,此次融资的投资方包括了强生公司、Atlas公司和Longevity Fund公司等。(生物谷Bioon.com)

详细英文报道:

A little more than a year ago, GlaxoSmithKline ($GSK) disbanded George Vlasuk's team at Sirtris and absorbed the R&D work in its Pennsylvania operations. But that didn't end the relationship. Today Vlasuk is back at the helm of a new biotech dubbed Navitor Pharmaceuticals, which was seeded initially by Polaris and is now coming out of stealth mode with a $23.5 million Series A and the backing of a syndicate that includes SR One, GlaxoSmithKline's venture arm.

This new Cambridge, MA-based venture, which also has drawn support from Johnson & Johnson ($JNJ) Development Corp., Atlas Venture, the Longevity Fund as well as additional cash from Polaris, is an example of a new breed of biotech. It is built on the lab work of a prestigious investigator and funded with a lean-and-mean plan to get into the clinic, and it's shooting at some big targets.

In this case the investigator in question is MIT Professor David Sabatini, who has spent years exploring the role of the mTOR kinase pathway in the development of various diseases. The mTOR pathway is targeted by rapamycin, Vlasuk tells FierceBiotech, but that drug blocks both the mTORC1 as well as the mTORC2 pathway when you really only want to target mTORC1 and leave mTORC2 alone. "It's mostly mTORC1 that becomes dysfunctional," says the CEO, and it is responsive to nutrient availability.

Navitor's job, with Sabatini's assistance, will be to both downregulate and upregulate the target, which can affect diseases ranging from diabetes to neurodegeneration and musculoskeletal conditions. Diabetes has largely been off-limits to small biotechs, which typically wouldn't have the resources needed to get a drug through late-stage testing. But Vlasuk is optimistic that he's attracting plenty of Big Pharma interest that could take something big forward, while reserving rare diseases and other more practical targets for the biotech.

"I think we have enough in this round to get us to a clinical candidate, says Vlasuk, who now has 6 full-timers on staff, including two from Sabatini's lab. Some potential partnerships could add to the runway, he adds.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->